Literature DB >> 19728526

Non-cystic fibrosis bronchiectasis.

Robert Cowie, Stephen Field.   

Abstract

Entities:  

Mesh：

Year:  2009        PMID： 19728526      PMCID： PMC4952524          DOI： 10.7861/clinmedicine.9-4-401

Source DB:  PubMed          Journal:  Clin Med (Lond)        ISSN： 1470-2118            Impact factor:   2.659


× No keyword cloud information.
  5 in total

Review 1.  An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases.

Authors:  David E Griffith; Timothy Aksamit; Barbara A Brown-Elliott; Antonino Catanzaro; Charles Daley; Fred Gordin; Steven M Holland; Robert Horsburgh; Gwen Huitt; Michael F Iademarco; Michael Iseman; Kenneth Olivier; Stephen Ruoss; C Fordham von Reyn; Richard J Wallace; Kevin Winthrop
Journal:  Am J Respir Crit Care Med       Date:  2007-02-15       Impact factor: 21.405

2.  Nontuberculous mycobacteria in bronchiectasis: Prevalence and patient characteristics.

Authors:  S J Fowler; J French; N J Screaton; J Foweraker; A Condliffe; C S Haworth; A R Exley; D Bilton
Journal:  Eur Respir J       Date:  2006-06-28       Impact factor: 16.671

3.  Non-tuberculous mycobacteria in patients with bronchiectasis.

Authors:  M Wickremasinghe; L J Ozerovitch; G Davies; T Wodehouse; M V Chadwick; S Abdallah; P Shah; R Wilson
Journal:  Thorax       Date:  2005-10-14       Impact factor: 9.139

4.  Treatment of Mycobacterium avium-intracellulare complex lung disease with a macrolide, ethambutol, and clofazimine.

Authors:  Stephen K Field; Robert L Cowie
Journal:  Chest       Date:  2003-10       Impact factor: 9.410

5.  Clarithromycin vs ciprofloxacin as adjuncts to rifampicin and ethambutol in treating opportunist mycobacterial lung diseases and an assessment of Mycobacterium vaccae immunotherapy.

Authors:  P A Jenkins; I A Campbell; J Banks; C M Gelder; R J Prescott; A P Smith
Journal:  Thorax       Date:  2008-02-04       Impact factor: 9.139
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.